Skip to content

DMT: all studies

Page 72 of 160: studies 711 to 720 of 1,593, newest first. Back to the DMT overview

Research

Mystical dynamics: renewal, luminous light, and ego disintegration as key features associated with mystical oneness—a psychometric analysis using the PES100 in controlled psychedelic studies

Religion, Brain & Behavior March 31, 2026 Kurt Stocker, Matthias Hartmann, Frederick S. Barrett et al.

Mystical dynamics—the notion that mystical oneness may unfold involving ego disintegration, renewal, and luminous light—has been discussed anecdotally by psychedelic researchers and therapists but has not yet been empirically examined in controlled settings. This study investigated the occurrence and dose-dependency of mystical dynamics in healthy participants after administration of...

DOI: 10.1080/2153599x.2026.2635353 (opens in new tab) Mysticism Psychometrics Key lock Psychometric testing +4

Beyond a Psychotropic Plant: Exploring the Ethnomedicinal Value of Anadenanthera colubrina var. cebil.

Mini-Reviews in Medicinal Chemistry March 30, 2026 Romina Belen González, Gonzalo Adrián Ojeda, Ana Melissa González Miragliotta et al.

Anadenanthera colubrina var. cebil (Griseb.) is an ecologically adaptable species native to South America, thriving across a variety of ecosystems, including the dry forests and savannas of Brazil, Argentina, Paraguay, and Bolivia, as well as the Andean highlands of Peru and Chile. Beyond its ecological significance, A. colubrina var. cebil is noted for its traditional use in ethnomedicine and...

Therapeutic Potential of Classical Psychedelics and NonHallucinogenic Psychoplastogens in Psychiatric Disorders

Psychiatry and Clinical Psychopharmacology March 30, 2026 Kenji Hashimoto, Feyza Arıcıoğlu, Mesut Çetin

Major depressive disorder remains a leading cause of disability worldwide, and current antidepressants are limited by delayed onset and incomplete response. Building on advances driven by ketamine research, renewed interest has focused on classical serotonergic psychedelics—particularly psilocybin, N,N-dimethyltryptamine (DMT), 5-methoxy-DMT, and lysergic acid diethylamide (LSD)—which, under...

When I use a word . . . Terminology of hallucinogenic agents

BMJ March 27, 2026 J K Aronson

Many terms have been invented to describe different types of hallucinogenic drugs, sometimes based on an analogy with the symptoms of schizophrenia, such as “psychotomimetic” and “phrenotropic.” “Psychedelics” refers to drugs that act as agonists at serotonin 5-HT2A receptors in the brain; they include psilocybin, 5-methoxydimethyltryptamine, and N,N-dimethyltryptamine (tryptamine derivatives),...

DOI: 10.1136/bmj.s606 (opens in new tab) Full text (opens in new tab) Terminology Word group theory Hallucinogen Medline +4

Classic psychedelic medicines for adolescent refractory mental health disease

Journal of Psychedelic Studies March 26, 2026 Aly Shah Aziz

Abstract Adolescent refractory mental health disorders are rising globally, contributing to long-term morbidity and substantial societal burden. Conventional psychotropic medications and psychotherapeutic approaches sometimes fail to provide adequate relief, necessitating an interest in novel investigational interventions. Classic psychedelic compounds—Psilocybin, Lysergic Acid Diethylamide...

Psilocybin: Chemical Foundations and Emerging Therapeutic Potential.

Mini-Reviews in Medicinal Chemistry March 24, 2026 Shivaputra A Patil, Holly C Hunsberger

Psilocybin, chemically known as (4-phosphoryloxy-N, N-dimethyltryptamine, 4-PODMT), is derived from the psychoactive mushroom genus, Psilocybe. Of the four active metabolites, psilocin readily enters systemic circulation. The psychoactive effects of psilocin are thought to arise through partial agonist effects at the 5-HT2A receptor. Psychedelic drugs, including psilocybin, are having a...

Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations

Expert Opinion on Pharmacotherapy March 24, 2026 Donatella Marazziti, Matteo Gambini, Riccardo Gurrieri et al.

INTRODUCTION: After decades of regulatory marginalization, psychedelic compounds have reemerged as promising therapeutic tools in psychiatry, driven by unmet clinical needs in treatment-resistant mental disorders and by growing evidence of rapid and sustained effects on mood, cognition, and behavior. AREAS COVERED: This narrative review critically examined the current clinical and regulatory...

DOI: 10.1080/14656566.2026.2654682 (opens in new tab) Clinical trial Medical prescription Medline Equity law +4

New psychoactive substances (designer drugs): an approach to classification

Neurology Bulletin March 23, 2026 Azat R. Asadullin, Elvina A. Akhmetova, Ilia S. Efremov et al.

BACKGROUND: Substance use disorders remain a global public health problem. In recent decades, the drug market has undergone substantial changes, with traditional drugs increasingly replaced by new psychoactive substances characterized by high toxicity and strong addictive potential. Their distribution via the Internet and social media impedes control and increases risks to public health. AIM:...

O ser espectral: consciência, estados expandidos e a arquitetura holográfica da realidade: Uma ontologia informacional da persistência e da percepção

Revista fisio&terapia March 22, 2026 Muriel Fernandes

Este artigo propõe uma interpretação híbrida, filosófica e teórico-estrutural, da consciência como padrão informacional dinâmico dentro da Arquitetura Holográfica da Construção da Realidade (AHCR). Partindo da hipótese de que a identidade pode ser compreendida como continuidade estrutural e não como substância fixa, o texto investiga a possibilidade de persistência informacional além da...

Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil.

Journal of Psychoactive Drugs March 20, 2026 Marina A. M. Portes, Leandro J Bertoglio

Psilocybin, N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA) are psychedelic compounds with therapeutic potential for depression, anxiety, and post-traumatic stress. However, their relevance to endurance athletes, who face particular psychological and physical stressors, remains underexplored. This study combines a conceptual overview...